The Food and Drug Administration (FDA) issued FDA Advisory No. 2026-0274 announcing the designation of an Officer of the Day (OOD) at the Food and Drug Action Center (FDAC). This initiative aims to ensure the continuous, efficient, and timely handling of urgent regulatory concerns, public inquiries, and emergency cases within the Food and Drug Administration (FDA).
The designation of an OOD strengthens FDA’s frontline regulatory response particularly in addressing immediate public health concerns, product-related incidents, regulatory clarifications, and emergency communications, while enhancing real-time coordination across FDA Centers.
Read the full advisory here: FDA-ADVISORY-NO.2026-0274.pdf
Purpose of the Advisory
To announce the designation of an Officer of the Day (OOD) at the Food and Drug Action Center (FDAC).
To ensure continuous, efficient, and timely handling of urgent regulatory concerns, public inquiries, and emergency cases within the Food and Drug Administration (FDA).
Scope of Application
This Advisory applies to stakeholders and members of the public seeking urgent regulatory assistance from the Food and Drug Administration (FDA).
Key Highlights
Establishment of Officer of the Day (OOD)
Establishes an Officer of the Day at the FDAC as a dedicated point person for urgent and emergency regulatory matters.
The OOD is responsible for:
- Receiving and responding to urgent queries, reports, and concerns from stakeholders and the public
- Coordinating with concerned FDA centers, offices, and units for immediate action and resolution
- Ensuring prompt documentation, escalation, and endorsement of urgent cases
- Facilitating effective communication between FDA and stakeholders
Supports improved regulatory accessibility, responsiveness, and operational efficiency.
Schedule of Designated Officer of the Day
Receiving Center | Schedule |
Center for Food Regulations and Research (CFRR) | Monday, 9:00 AM – 4:00 PM |
Center for Drugs Regulation and Research (CDRR) | Tuesday and Wednesday, 9:00 AM – 4:00 PM |
Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research (CCHUHSRR) | Thursday, 9:00 AM – 4:00 PM |
Center for Device Regulation, Radiation Health and Research (CDRRHR) | Friday, 9:00 AM – 4:00 PM |
Implications to Clients
FDA Advisory No. 2026-0274 strengthens the FDA’s public service delivery framework by institutionalizing a dedicated and accessible point of contact at the FDAC for urgent matters.
Clients may expect faster regulatory coordination, clearer communication, and improved responsiveness, particularly for cases requiring immediate regulatory attention or intervention.
Effective Date
February 16, 2026
For Inquiries
For inquiries or support regarding medical device regulatory requirements in the Philippines, please contact sales@andamanmed.com.
